Download PDF
Exp Clin Endocrinol Diabetes 2019; 127(01): 68-75
DOI: 10.1055/s-0042-105282
Article
© Georg Thieme Verlag KG Stuttgart · New York

Zoledronic Acid Improves Bone Quality in the Streptozotocin-Induced Diabetes Rat through Affecting the Expression of the Osteoblast-Regulating Transcription Factors

M. Cui
1   Department of Pain Management, Jinan Central Hospital affiliated to Shandong University, Jinan, People’s Republic of China
,
L.-Z Yu
1   Department of Pain Management, Jinan Central Hospital affiliated to Shandong University, Jinan, People’s Republic of China
,
N. Zhang
1   Department of Pain Management, Jinan Central Hospital affiliated to Shandong University, Jinan, People’s Republic of China
,
L.-J. Wang
2   Department of Anesthesiology, Jinan Central Hospital affiliated to Shandong University, Jinan, People’s Republic of China
,
J. Sun
3   Department of Pain Management, Binzhou Medical University Hospital, Binzhou, People’s Republic of China
,
J. Cong
4   Department of Anesthesiology, Wendeng Central Hospital of Wei Hai, Weihai, People’s Republic of China
› Author Affiliations
Further Information

Publication History

received  29 December 2015
revised   02 March 2016

accepted 09 March 2016

Publication Date:
29 June 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Aims To evaluate the short term effect of zoledronic acid on bone remodeling in the streptozotocin induced diabetes rats.

Materials and Methods Diabetes was induced by an injection of streptozotocin (60 mg/kg). The rats were treated with zoledronic acid (0.1 mg/kg) at the onset of diabetes (Z-I group) and 2 weeks later (Z-II group). Rats were sacrificed at the 1, 2, 3, 4 and 5 weeks after the onset of diabetes. Real–time PCR and western blot were performed to detect the expression of the following osteogenic gene mRNAs and their proteins: bone morphogenetic proteins 2 (BMP2), Runx2, Osterix and Noggin. The bone mineral density (BMD) and the mechanical resistance test was measured.

Results BMP2, Runx2 and Osterix mRNA and protein expression in group D had regulated down, while Noggin expression increased. Z-I treatment could reverse the results. However group Z-II showed only a transient reversing effect. On the 5th week in group D, the BMD decreased, the bone trabecular distance increased, while the trabecular thickness and bone trabecular volume were reduced, the biomechanics index decreased significantly. Zoledronic acid treatment restored these alterations.

Conclusions Zoledronic acid administered in the early stage of the diabetes could prevent the osteopenia. The underlying mechanisms might be that zoledronic acid treatment reversed the effect of diabetes on the expression of osteoblast-regulating transcription factors: BMP2, Runx2 and Osterix.

Key words

bisphosphonates - osteopenia - diabetes mellitus
 

  • References

  • 1 Kemink SA, Hermus AR, Swinkels LM. et al. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. Journal of endocrinological investigation 2000; 23: 295-303
    CrossrefPubMedGoogle Scholar
  • 2 Derenne S, Amiot M, Barille S. et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 1999; 14: 2048-2056
    CrossrefPubMedGoogle Scholar
  • 3 Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 2006; 39: 443-452
    CrossrefPubMedGoogle Scholar
  • 4 Frediani B, Spreafico A, Capperucci C. et al. Long-term effects of neridronate on human osteoblastic cell cultures. Bone 2004; 35: 859-869
    CrossrefPubMedGoogle Scholar
  • 5 Cohen Jr MM. Bone morphogenetic proteins with some comments on fibrodysplasia ossificans progressiva and NOGGIN. American journal of medical genetics 2002; 109: 87-92
    CrossrefPubMedGoogle Scholar
  • 6 Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocrine reviews 2003; 24: 218-235
    CrossrefPubMedGoogle Scholar
  • 7 Nakashima K, Zhou X, Kunkel G. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cells 2002; 108: 17-29
    PubMedGoogle Scholar
  • 8 Baek WY, Lee MA, Jung JW. et al. Positive regulation of adult bone formation by osteoblast-specific transcription factor osterix. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 2009; 24: 1055-1065
    CrossrefPubMedGoogle Scholar
  • 9 Lozano D, de Castro LF, Dapia S. et al. Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia. Endocrinology 2009; 150: 2027-2035
    CrossrefPubMedGoogle Scholar
  • 10 Lu H, Kraut D, Gerstenfeld LC. et al. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology 2003; 144: 346-352
    CrossrefPubMedGoogle Scholar
  • 11 Botolin S, Faugere MC, Malluche H. et al. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology 2005; 146: 3622-3631
    CrossrefPubMedGoogle Scholar
  • 12 Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone 1993; 14: 595-608
    CrossrefPubMedGoogle Scholar
  • 13 Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiological research/Academia Scientiarum Bohemoslovaca 2001; 50: 537-546
    PubMedGoogle Scholar
  • 14 von Knoch F, Jaquiery C, Kowalsky M. et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005; 26: 6941-6949
    CrossrefPubMedGoogle Scholar
  • 15 Plotkin LI, Bivi N, Bellido T. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone 2011; 49: 122-127
    CrossrefPubMedGoogle Scholar
  • 16 Gasser JA, Green JR, Shen V. et al. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats. Bone 2006; 39: 787-795
    CrossrefPubMedGoogle Scholar
  • 17 Recker RR, Delmas PD, Halse J. et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 2008; 23: 6-16
    PubMedGoogle Scholar
  • 18 Giuliani N, Pedrazzoni M, Negri G. Bisphosphonates Stimulate Formation of Osteoblast Precursors and Mineralized Nodules in Murine and Human Bone Marrow Cultures In Vitro and Promote Early Osteoblastogenesis in Young and Aged Mice In Vivo. Bone 1998; 22: 455-461
    CrossrefPubMedGoogle Scholar
  • 19 McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. Journal of cellular biochemistry 2007; 102: 1343-1357
    CrossrefPubMedGoogle Scholar
  • 20 Gazzerro E, Gangji V, Canalis E. Bone morphogenetic proteins induce the expression of Noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 1998; 102: 2106-2114
    CrossrefPubMedGoogle Scholar
  • 21 Komori T. Regulation of osteoblast differentiation by transcription factors. Journal of cellular biochemistry 2006; 99: 1233-1239
    CrossrefPubMedGoogle Scholar
  • 22 Nakashima K, de Crombrugghe B. Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends in Genetics 2003; 19: 458-466
    CrossrefPubMedGoogle Scholar
  • 23 Hie M, Tsukamoto I. Increased expression of the receptor for activation of NF-κB and decreased runt-related transcription factor 2 expression in bone of rats with streptozotocin-induced diabetes. International Journal of Molecular Medicine 2010; 26
    PubMed
  • 24 Moyer-Mileur LJ, Slater H, Jordan KC. et al. IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 2008; 23: 1884-1891
    CrossrefPubMedGoogle Scholar
  • 25 Coe LM, Tekalur SA, Shu Y. et al. Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation. Journal of cellular physiology 2015; 230: 1944-1953
    CrossrefPubMedGoogle Scholar